Acute Respiratory Distress Syndrome Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Acute Respiratory Distress Syndrome Overview

The tiny, elastic air sacs (alveoli) in your lungs experience fluid buildup, which results in acute respiratory distress syndrome (ARDS). Less oxygen enters your circulation because of the fluid’s ability to prevent your lungs from filling with enough air. Your organs are deprived of the oxygen they require to function as a result.

“Acute Respiratory Distress Syndrome Pipeline Insight, 2023″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Acute Respiratory Distress Syndrome Market.

The Acute Respiratory Distress Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Acute Respiratory Distress Syndrome Pipeline Report: https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-pipeline-insight

• Companies across the globe are diligently working toward developing novel Acute Respiratory Distress Syndrome treatment therapies with a considerable amount of success over the years. Acute Respiratory Distress Syndrome Key players such as – Veru, Vanda Pharmaceuticals, Foresee Pharmaceuticals, Athersys, Meridigen Biotech, AVM Biotechnology, Aqualung Therapeutics, Cynata Therapeutics, Histocell, BioMarck Pharmaceuticals, Exvastat, Vasomune Therapeutics, Athersys, and others, are developing therapies for the Acute Respiratory Distress Syndrome treatment 

• Acute Respiratory Distress Syndrome Emerging therapies such as – VERU-111, Tradipitant, FP-025, HLCM051 (MultiStem), UMC 119 06, AVM0703, ALT-100, CYP 001, HCR040, BIO-11006, Imatinib, AV 001, MultiStem cell therapy, and others are expected to have a significant impact on the Acute Respiratory Distress Syndrome market in the coming years.   
• In February 2021, Athersys announced that it had entered into a cooperation agreement with HEALIOS. The cooperation agreement is intended to reaffirm the mutual commitment to the collaborative development of MultiStem in Japan.
• In March 2021, Partner Therapeutics announced a licensing and collaboration agreement with SIRS Therapeutics and F4 Pharma to support the development of FX-06. This synthetic peptide has a broad spectrum of potential indications 

Route of Administration

Acute Respiratory Distress Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy 

Acute Respiratory Distress Syndrome Pipeline Therapeutics Assessment

• Acute Respiratory Distress Syndrome Assessment by Product Type
• Acute Respiratory Distress Syndrome By Stage and Product Type
• Acute Respiratory Distress Syndrome Assessment by Route of Administration
• Acute Respiratory Distress Syndrome By Stage and Route of Administration
• Acute Respiratory Distress Syndrome Assessment by Molecule Type
• Acute Respiratory Distress Syndrome by Stage and Molecule Type

DelveInsight’s Acute Respiratory Distress Syndrome Report covers around 60+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of the key companies in the Acute Respiratory Distress Syndrome Therapeutics Market include:

Key companies developing therapies for Acute Respiratory Distress Syndrome are – Athersys, Inc, Histocell, BioXcellerator, Altor BioScience, Cartesian Therapeutics, Meridigen Biotech Co., Ltd., Sage Therapeutics, Healios K.K., Chiesi Farmaceutici, Bayer, Altor BioScience, Faron Pharmaceuticals Ltd, AVM Biotechnology LLC, Amyndas Pharmaceuticals S.A., Kinevant Sciences GmbH, Eli Lilly and Company, Suntory Pharmaceutical, Alexion Pharmaceuticals, Laboratoire français de Fractionnement et de Biotechnologies (LFB), Evgen Pharma, Dimerix Bioscience, Mylan, Vanda Pharmaceuticals, Kiniksa Pharmaceuticals Foresee Pharmaceuticals, Boehringer Ingelheim, Staidson (Beijing) Biopharmaceuticals, Biohaven Pharmaceuticals, Chimerix, Edesa Biotech, and others

Emerging Acute Respiratory Distress Syndrome Drugs Under Different Phases of Clinical Development Include:

• VERU-111: Veru
• Tradipitant: Vanda Pharmaceuticals
• FP-025: Foresee Pharmaceuticals
• HLCM051 (MultiStem): Athersys
• UMC 119 06: Meridigen Biotech
• AVM0703: AVM Biotechnology
• ALT-100: Aqualung Therapeutics
• CYP 001: Cynata Therapeutics
• HCR040: Histocell
• BIO-11006: BioMarck Pharmaceuticals
• Imatinib: Exvastat
• AV 001: Vasomune Therapeutics
• MultiStem cell therapy: Athersys

Get a Free Sample PDF Report to know more about Acute Respiratory Distress Syndrome Pipeline Therapeutic Assessment-

https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-pipeline-insight

Acute Respiratory Distress Syndrome Pipeline Analysis:

The Acute Respiratory Distress Syndrome pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Acute Respiratory Distress Syndrome with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Respiratory Distress Syndrome Treatment.
• Acute Respiratory Distress Syndrome key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Acute Respiratory Distress Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acute Respiratory Distress Syndrome market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Acute Respiratory Distress Syndrome product details are provided in the report. Download the Acute Respiratory Distress Syndrome pipeline report to learn more about the emerging Acute Respiratory Distress Syndrome therapies

Acute Respiratory Distress Syndrome Pipeline Market Drivers

• Increasing R&D activities
• Increasing incidence of Acute Respiratory Distress Syndrome
• Non-competitive Landscape

Acute Respiratory Distress Syndrome Pipeline Market Barriers

• Lack of awareness about the disease
• Mechanical ventilation for management
• Missed-diagnoses of Acute Respiratory Distress Syndrome

Scope of Acute Respiratory Distress Syndrome Pipeline Drug Insight    

• Coverage: Global
• Key Acute Respiratory Distress Syndrome Companies: Veru, Vanda Pharmaceuticals, Foresee Pharmaceuticals, Athersys, Meridigen Biotech, AVM Biotechnology, Aqualung Therapeutics, Cynata Therapeutics, Histocell, BioMarck Pharmaceuticals, Exvastat, Vasomune Therapeutics, Athersys, and others
• Key Acute Respiratory Distress Syndrome Therapies: VERU-111, Tradipitant, FP-025, HLCM051 (MultiStem), UMC 119 06, AVM0703, ALT-100, CYP 001, HCR040, BIO-11006, Imatinib, AV 001, MultiStem cell therapy, and others
• Acute Respiratory Distress Syndrome Therapeutic Assessment: Acute Respiratory Distress Syndrome current marketed and Acute Respiratory Distress Syndrome emerging therapies
• Acute Respiratory Distress Syndrome Market Dynamics: Acute Respiratory Distress Syndrome market drivers and Acute Respiratory Distress Syndrome market barriers 

Request for Sample PDF Report for Acute Respiratory Distress Syndrome Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Acute Respiratory Distress Syndrome drugs and therapies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting